Pancreatic Somatostatinoma. Clinical Features and Physiological Implications
Overview
Authors
Affiliations
The first case of a tumour producing somatostatin-like immunoreactivity and bioactivity is presented. The pancreatic tumour was composed of cells indistinguishable from islet D cells. Radioimmunoassay of blood-samples obtained by tumour-vein catheterisation revealed very high levels of somatostatin immunoreactivity. On gel chromatography tumour extracts were found to contain at least 4 different immunoreactive components, one of which eluted in the position of synthetic somatostatin. Extracts from the tumour were potent in inhibiting insulin and glucagon secretion from isolated perfused porcine pancreas. Clinical abnormalities included hypochlorhydria, steatorrhoea, and diabetic glucose tolerance. Conceivably some of these abnormalities may be related to somatostatin hypersecretion from the pancreatic tumour.
Clinicopathological Data and Treatment Modalities for Pancreatic Somatostatinomas.
Mastoraki A, Schizas D, Papoutsi E, Ntella V, Kanavidis P, Sioulas A In Vivo. 2020; 34(6):3573-3582.
PMID: 33144470 PMC: 7811659. DOI: 10.21873/invivo.12201.
Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms.
Hofland J, Kaltsas G, de Herder W Endocr Rev. 2019; 41(2).
PMID: 31555796 PMC: 7080342. DOI: 10.1210/endrev/bnz004.
Somatostatinoma syndrome: a challenging differential diagnosis among pancreatic tumors.
Vianna P, Ferreira C, de Campos F Autops Case Rep. 2019; 3(1):29-37.
PMID: 31528595 PMC: 6671881. DOI: 10.4322/acr.2013.005.
Evaluation and Management of Neuroendocrine Tumors of the Pancreas.
Scott A, Howe J Surg Clin North Am. 2019; 99(4):793-814.
PMID: 31255207 PMC: 6601637. DOI: 10.1016/j.suc.2019.04.014.
Somatostatinoma Presented as Double-Duct Sign.
Zakaria A, Hammad N, Vakhariya C, Raphael M Case Rep Gastrointest Med. 2019; 2019:9506405.
PMID: 31210994 PMC: 6532322. DOI: 10.1155/2019/9506405.